How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom
In a precedential June 23 decision in Enanta Pharmaceuticals Inc. v. Pfizer Inc.,[1] the U.S. Court of Appeals for the Federal Circuit held that Enanta's asserted Paxlovid-related claims could not rely on a provisional...To view the full article, register now.
Already a subscriber? Click here to view full article